HPLC determination and pharmacokinetic study of tenatoprazole in dog plasma after oral administration of enteric-coated capsule

Biomedical Chromatography

Volumn 21, Issue 1, 2007, Pages 89-93

  Liu, Pei ^a   Sun, Bo ^a   Lu, Xiumei ^a   Qin, Feng ^a   Li, Famei ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Enteric coated capsule; HPLC; Pharmacokinetics; Tenatoprazole

Indexed keywords

BIOCHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

CHROMATOGRAPHIC DETERMINATION; DOG PLASMA; ENTERIC-COATED CAPSULES; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC METHODS; INTERNAL STANDARDS; ORAL ADMINISTRATION; PERFORMANCE; PHARMACOKINETIC STUDIES; TENATOPRAZOLE;

PHARMACOKINETICS;

ACETONITRILE; BENATOPRAZOLE; BUFFER; ETHER; PANTOPRAZOLE; PHOSPHATE; PROTON PUMP INHIBITOR;

ACCURACY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DEGRADATION; DRUG DETERMINATION; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; ENTERIC COATED TABLET; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PH; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; ULTRAVIOLET SPECTROSCOPY;

CANIS FAMILIARIS;

EID: 33846519412     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.724     Document Type: Article

References (6)

1. Chun AH, Erdman K, Zhang Y, Achari R and Cavanaugh JH. Effect on bioavailability of admixing the contents of lansoprazole capsules with selected soft foods. Clinical Therapeutics 2000; 22: 231-236.
2. Johnson DA, Roach AC, Carlsson AS, Karlsson AA and Behr DE. Stability of esomeprazole capsule contents after in vitro suspension in common soft foods and beverages. Pharmacotherapy 2003; 23: 731-734.
3. Larson C, Cavuto NJ, Flockhart DA and Weinberg RB. Bioavailability and efficacy of omeprazole given orally and by nasogastric tube. Digestive Diseases and Sciences 1996; 41: 475-479.
4. Saito S, Sebata N, Ishiwata T, Kinbara M and Morotome K. Pharmacokinetic Studies of (±)-5-Methoxy-2-(4-methoxy-3,5- dimethylpyrid-2-yl)methyl]sulfinyl]-1H-imidazo[4,5-b]pyridine (TU-199). Iyakuhin Kenkyu 1999; 30: 119-127.
5. +-ATPase in vitro and in vivo. Biochemical Pharmacology 2006; 71: 837-849.
6. +-ATPase inhibitor, on gastric acid secretion in dogs. The Journal of Pharmacy and Pharmacology 1999; 51(4): 457-464.